Your Location:Home >Products >API >249296-44-4

249296-44-4

  • Product Name:Vareniclina
  • Molecular Formula:C13H13N3
  • Molecular Weight:211.266
Inquiry

Product Details

pd_meltingpoint:138.5 °C

Purity:99%

Offer Chemical Raw Material Vareniclina 249296-44-4 In Stock

  • Molecular Formula:C13H13N3
  • Molecular Weight:211.266
  • Vapor Pressure:1.25E-06mmHg at 25°C 
  • Melting Point:138.5 °C 
  • Refractive Index:1.667 
  • Boiling Point:400.6 °C at 760 mmHg 
  • PKA:9.60±0.20(Predicted) 
  • Flash Point:196.1 °C 
  • PSA:152.87000 
  • Density:1.247 g/cm3 
  • LogP:0.01010 

Varenicline(Cas 249296-44-4) Usage

Synthesis

Several modifications to the original synthesis have been reported in the literature, including an improved process scale synthesis of the last few steps.The Grignard reaction was initiated on a small scale by addition of 2-bromo fluorobenzene 113 to a slurry of Magnesium turnings and catalytic 1,2-dibromoethane in THF and heating the mixture until refluxing in maintained. To this refluxing mixture was added a mixture of the 2-bromo fluorobenzene 113 and cyclopentadiene 114 over a period of 1.5 h. After complete addition, the reaction was allowed to reflux for additional 1.5 h to give the Diels- Alder product 115 in 64% yield. Dihydroxylation of the olefin 115 by reacting with catalytic osmium tetraoxide in the presence of N-methylmorpholine N-oxide (NMO) in acetone: water mixture at room temperature provided the diol 116 in 89% yield. Oxidative cleavage of diol 116 with sodium periodate in biphasic mixture of water: DCE at 10oC provided di-aldehyde 117 which was immediately reacted with benzyl amine in the presence of sodium acetoxyborohydride to give benzyl amine 118 in 85.7% yield. The removal of the benzyl group was effected by hydrogenation of the HCl salt in 40-50 psi hydrogen pressure with 20% Pd(OH)2 in methanol to give amine hydrochloride 119 in 88% yield. Treatment of amine 119 with trifluoroacetic anhydride and pyridine in dichloromethane at 0oC gave trifluoroacetamide 120 in 94% yield. Dinitro compound 121 was prepared by addition of trifluoroacetamide 120 to a mixture of trifluoromethane sulfonic acid and nitric acid, which was premixed, in dichloromethane at 0oC. Reduction of the dinitro compound 121 by hydrogenation at 40-50 psi hydrogen in the presence of catalytic 5%Pd/C in isopropanol:water mixture provided the diamine intermediate 122 which was quickly reacted with glyoxal in water at room temperature for 18h to give compound 123 in 85% overall yield. The trifluoroacetamide 123 was then hydrolyzed with 2 M sodium hydroxide in toluene at 37-40oC for 2-3h followed by preparation of tartrate salt in methanol to furnish varenicline tartrate (XV).

Drug interactions

Potentially hazardous interactions with other drugs None known

Metabolism

Varenicline undergoes minimal metabolism with less than 10% excreted as metabolites. About 92% of a dose is excreted unchanged in the urine. Minor metabolites in urine include varenicline N-carbamoylglucuronide, N-glucosylvarenicline and hydroxyvarenicline. In circulation, varenicline comprises 91% of drug-related material.

references

[1] garrison gd, dugan se. varenicline: a first-line treatment option for smoking cessation. clin ther. 2009 mar;31(3):463-91.

Definition

ChEBI: An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.

Brand name

Chantix (Pfizer).

InChI:InChI=1/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2

249296-44-4 Relevant articles

Varenicline synthesis method

-

Paragraph 0024; 0036, (2021/07/31)

The present invention relates to a proce...

Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof

-

, (2021/06/23)

Provided is a cocrystal of varenicline a...

IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED QUINOXALINES

-

, (2011/07/30)

The present invention is directed to an ...

HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY

-

, (2011/10/05)

Provided herein is an impurity of vareni...

249296-44-4 Process route

N-benzylvarenicline

N-benzylvarenicline

varenicline
249296-44-4

varenicline

Conditions
Conditions Yield
With palladium 10% on activated carbon; hydrogen; In methanol; for 3h; under 760.051 Torr;
90%
5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]hexadeca-2<sup>(11)</sup>,3,5,7,9-pentaene sulfate
1333145-92-8

5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]hexadeca-2(11),3,5,7,9-pentaene sulfate

varenicline
249296-44-4

varenicline

Conditions
Conditions Yield
With sodium hydroxide; In water; at 20 - 30 ℃; for 0.5h; pH=12.5 - 13.5;
83%

249296-44-4 Upstream products

  • 230615-70-0
    230615-70-0

    1-(9,10-dihydro-6H-6,10-methanoazepino[4,5-g]quinoxaline-8(7H)-yl)-2,2,2,-trifluoroethanone

  • 230615-56-2
    230615-56-2

    1-(4-amino-10-aza-tricyclo[6.3.1.02,7]dodeca-2,4,6-trien-10-yl)-2,2,2-trifluoro-ethanone

  • 1197286-22-8
    1197286-22-8

    5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]hexadeca-2(11).3.5,7,9-pentaene tosylate

  • 1206484-38-9
    1206484-38-9

    C21H21N3O

249296-44-4 Downstream products

  • 375815-87-5
    375815-87-5

    varenicline L-tartarate

  • 1197286-22-8
    1197286-22-8

    5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]hexadeca-2(11).3.5,7,9-pentaene tosylate

Relevant Products